1029 related articles for article (PubMed ID: 19276451)
1. Why are a high overdiagnosis probability and a long lead time for prostate cancer screening so important?
Barry MJ; Mulley AJ
J Natl Cancer Inst; 2009 Mar; 101(6):362-3. PubMed ID: 19276451
[No Abstract] [Full Text] [Related]
2. Re: Prostate cancer diagnosis and treatment after the introduction of prostate-specific antigen screening: 1986-2005.
Belpomme D; Irigaray P
J Natl Cancer Inst; 2010 Apr; 102(7):506-7. PubMed ID: 20190186
[No Abstract] [Full Text] [Related]
3. Lung cancer screening gets risk-specific.
Peres J
J Natl Cancer Inst; 2013 Jan; 105(1):1-2. PubMed ID: 23257155
[No Abstract] [Full Text] [Related]
4. Screening for prostate cancer - will we ever know?
Adolfsson J
Acta Oncol; 2010 Apr; 49(3):275-7. PubMed ID: 20397764
[No Abstract] [Full Text] [Related]
5. Efficacy vs effectiveness in prostate-specific antigen screening.
Albertsen PC
J Natl Cancer Inst; 2010 Mar; 102(5):288-9. PubMed ID: 20142583
[No Abstract] [Full Text] [Related]
6. Estimating lead time and overdiagnosis associated with PSA screening from prostate cancer incidence trends.
Telesca D; Etzioni R; Gulati R
Biometrics; 2008 Mar; 64(1):10-9. PubMed ID: 17501937
[TBL] [Abstract][Full Text] [Related]
7. Is screening for prostate cancer the current gold standard?--"no".
Kramer BS; Gohagan JK; Prorok PC
Eur J Cancer; 1997 Mar; 33(3):348-53. PubMed ID: 9155515
[No Abstract] [Full Text] [Related]
8. [Detection of prostate cancer: yes or no?].
Van Cangh PJ
Bull Mem Acad R Med Belg; 2006; 161(3-4):159-69. PubMed ID: 17172224
[No Abstract] [Full Text] [Related]
9. Assessing risk: does this patient have prostate cancer?
Carter HB
J Natl Cancer Inst; 2006 Apr; 98(8):506-7. PubMed ID: 16622114
[No Abstract] [Full Text] [Related]
10. Risks of PSA screening now better understood.
Peres J
J Natl Cancer Inst; 2013 Nov; 105(21):1590-2. PubMed ID: 24142893
[No Abstract] [Full Text] [Related]
11. Prostate cancer screening; is this a teachable moment?
Brawley OW
J Natl Cancer Inst; 2009 Oct; 101(19):1295-7. PubMed ID: 19720970
[No Abstract] [Full Text] [Related]
12. Serum prostate-specific antigen for the early detection of prostate cancer: always, never, or only sometimes?
Carroll PR; Whitson JM; Cooperberg MR
J Clin Oncol; 2011 Feb; 29(4):345-7. PubMed ID: 21189396
[No Abstract] [Full Text] [Related]
13. Continued undertreatment of older men with localized prostate cancer.
Carter HB
Urology; 2004 Jul; 64(1):189-90; author reply 190. PubMed ID: 15245976
[No Abstract] [Full Text] [Related]
14. Early diagnosis of prostate cancer: the continuing debate on the impact on mortality.
Höltl W; Lunglmayr G
Wien Klin Wochenschr; 2005 Jul; 117(13-14):440-1. PubMed ID: 16091868
[No Abstract] [Full Text] [Related]
15. Solving the overdiagnosis dilemma.
Esserman L; Thompson I
J Natl Cancer Inst; 2010 May; 102(9):582-3. PubMed ID: 20413743
[No Abstract] [Full Text] [Related]
16. Lead time of prostate cancer detected in population based screening for prostate cancer in Japan.
Ito K; Yamamoto T; Miyakubo M; Takechi H; Ohi M; Shibata Y; Suzuki K
J Urol; 2007 Oct; 178(4 Pt 1):1258-63; discussion 1263-4. PubMed ID: 17698107
[TBL] [Abstract][Full Text] [Related]
17. States renewing attention to prostate cancer.
Rossiter C
NCSL Legisbrief; 2012 Sep; 20(36):1-2. PubMed ID: 23072022
[No Abstract] [Full Text] [Related]
18. Prostate cancer: screening and early detection.
Tariman JD
Adv Nurse Pract; 2006 Sep; 14(9):20. PubMed ID: 16972436
[No Abstract] [Full Text] [Related]
19. The cautionary tale of PSA testing.
Hoffman RM; Zeliadt SB
Arch Intern Med; 2010 Jul; 170(14):1262-3. PubMed ID: 20660847
[No Abstract] [Full Text] [Related]
20. Re: Prostate-specific antigen: a misused and maligned prostate cancer biomarker.
Hamilton RJ; Platz EA; Freedland SJ
J Natl Cancer Inst; 2009 Apr; 101(8):611-2. PubMed ID: 19351913
[No Abstract] [Full Text] [Related]
[Next] [New Search]
